These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37053548)

  • 1. Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease.
    Yang JY; Lund JL; Funk MJ; Hudgens MG; Lewis JD; Kappelman MD;
    Am J Gastroenterol; 2023 Sep; 118(9):1638-1647. PubMed ID: 37053548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019.
    Yang JY; Lund JL; Pate V; Kappelman MD
    Inflamm Bowel Dis; 2023 May; 29(5):735-743. PubMed ID: 35929644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
    Ehrenberg R; Griffith J; Theigs C; McDonald B
    J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease.
    Abadir A; Troia A; Said H; Tarugu S; Billingsley BC; Sairam N; Minchenberg SB; Owings AH; Parker AM; Brousse B; Carlyle A; Owens BR; Hosseini-Carroll P; Galeas-Pena M; Frasca J; Glover SC; Papamichael K; Cheifetz AS
    Dig Dis Sci; 2024 Aug; 69(8):2796-2803. PubMed ID: 38963462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
    Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study.
    Mateescu RB; Gheorghe C; Trifan AV; Saftoiu A; Seicean A; Diculescu MM; Banciu C; Gheorghe LS; Busuioc B; Goldis A; Dobru D; Fratila O; Eugen D; Bataga S; Constantinescu G; Gheonea D; Tantau A; Jinga M; Brisc C; Cijevschi Prelipcean C; Chira R; Fierbințeanu-Braticevici C; Dumitrascu D; State M; Voiosu T; Negreanu L
    J Gastrointestin Liver Dis; 2023 Dec; 32(4):444-451. PubMed ID: 38147607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
    Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.